JDNPPA is the only independent, omni-channel resource that is for dermatology NPs and PAs and by NPs and PAs.
Joined March 2024
- Tweets971
- Following294
- Followers42
- Likes1.1K
US FDA approves tildrakizumab-asmn (#Ilumya, @SunPharma_Live) for the treatment of adults with active #psoriaticarthritis (#PsA). jdnppa.com/news-your-psa-pat…
JDNPPA retweeted
Join Leigh Ann Pansch, MSN, FNP-BC, DCNP, for a discussion on earlier intervention with #COSENTYX® (secukinumab). *Bonus: Stay for a session on social media engagement with Steven Daveluy, MD! REGISTER HERE: inceptionmeetings.com/Dermat…
Current barriers to early PsA detection are multifactorial and systemic. Many patients with psoriasis remain unaware of their risk for developing arthritis, leading to delays in reporting musculoskeletal symptoms. digitaleditions.walsworth.co…
JDNPPA retweeted
Infants born to mothers who ate a healthy, Mediterranean-style diet during pregnancy were at lower risk for colic and #eczema, according to a new study in @JAMANetworkOpen. jdnppa.com/can-eating-a-heal…
JDNPPA retweeted
A 34-year-old man experienced about a year of intense facial flushing before developing classic papulopustular #rosacea. A six-month course of sub-antimicrobial doxycycline in combination with topical metronidazole 1% gel led to marked improvement in both papules & pustules. However, the patient still demonstrated bothersome facial skin sensitivity, erythema, and bouts of flushing. Continue reading: tdd.mydigitalpublication.com…
The management of severe #atopicdermatitis (AD) in children under age 12 remains a significant clinical challenge. digitaleditions.walsworth.co…
#EczemaAwarenessMonth
JDNPPA retweeted
#Dermatology PA, Kara Mudd, DMSc, MSPAS, PA-C shares more about her role on the Advisory Council for Maui Derm, and gives insight into why PAs and NPs should join her at the next #MauiDerm meeting in Summer 2027!
JDNPPA retweeted
The US FDA approved remibrutinib (#Rhapsido, @NovartisCT) for adults with symptomatic #dermographism (SD) inadequately controlled by H1 antihistamines. Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), is the first and only treatment for adults with SD. jdnppa.com/us-fda-approves-f…
[NEW ISSUE] In advance of #WorldPsoriasisDay, our newest cover story explores how #dermatology & #rheumatology advanced practice providers can collaborate to optimize outcomes for patients with psoriatic disease. #WeekendRead digitaleditions.walsworth.co…
JDNPPA retweeted
The advent of novel non-steroidal targeted topicals, including ruxolitinib cream, have expanded the therapeutic toolbox, providing more options for #atopicdermatitis patients who don’t want to or can’t use topical corticosteroids. tdd.mydigitalpublication.com…
JDNPPA retweeted
Oral icotrokinra (#Icotyde, JNJ) produces durable skin clearance on high-impact #plaquepsoriasis (PsO) sites, new research shows. jdnppa.com/oral-icotrokinra-…
Join Leigh Ann Pansch, MSN, FNP-BC, DCNP, for a discussion on earlier intervention with #COSENTYX® (secukinumab). *Bonus: Stay for a session on social media engagement with Steven Daveluy, MD! REGISTER HERE: inceptionmeetings.com/Dermat…
JDNPPA retweeted
Oral Janus kinase (JAK) inhibitors should be first-line therapy for adults with severe #alopecia areata, according to the first-ever standardized treatment recommendations for these patients. jdnppa.com/its-time-to-rethi…
Infants born to mothers who ate a healthy, Mediterranean-style diet during pregnancy were at lower risk for colic and #eczema, according to a new study in @JAMANetworkOpen. jdnppa.com/can-eating-a-heal…
JDNPPA retweeted
The US FDA has approved pritelivir (#Hovilpri, Asahi Kasei Therapeutics) tablets for immunocompromised adults with mucocutaneous lesions caused by #herpessimplex virus (#HSV) infection who have not responded to treatment with acyclovir, valacyclovir, or famciclovir. thedermdigest.com/us-fda-app…
#Dermatology PA, Kara Mudd, DMSc, MSPAS, PA-C shares more about her role on the Advisory Council for Maui Derm, and gives insight into why PAs and NPs should join her at the next #MauiDerm meeting in Summer 2027!
JDNPPA retweeted
The last two episodes in our roundtable series are now available! 📺 Check them out or catch up on all eight episodes released this month! jdnppa.com/videos/refining-t…
JDNPPA retweeted
🆕 🆕 🆕 This broadcast will explore the science behind Cloud-Tech™ & how the Neutrogena® formulation expertise helps optimize both protection & wearability, supporting the features patients want in a daily sunscreen. Register: inceptionmeetings.com/Dermat…
JDNPPA retweeted
From identifying appropriate candidates for #GLP1 RAs to recognizing potential dermatologic complications associated with their use, Laura Bush DMSc, PA-C, DFAAPA, shares practical insights on using these agents in patients with #skindisease and obesity. jdnppa.com/what-every-dermat…
The US FDA approved remibrutinib (#Rhapsido, @NovartisCT) for adults with symptomatic #dermographism (SD) inadequately controlled by H1 antihistamines. Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), is the first and only treatment for adults with SD. jdnppa.com/us-fda-approves-f…